Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.041
Sell
RSI(14)
32.321
Neutral
STOCH(KDJ)(9,3,3)
29.556
Neutral
ATR(14)
0.097
High Vlolatility
CCI(14)
-120.970
Sell
Williams %R
83.721
Oversold
TRIX(12,20)
-0.596
Sell
StochRSI(14)
40.928
Sell
TELA Bio Inc
TELA1.200USD
-0.090-6.98%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
47.50MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of TELA Bio Inc
Currency: USD Updated: 2025-11-05Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TELA Bio Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
5.400
Target Price
+318.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
TELA Bio Inc Highlights
StrengthsRisks
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 67.32% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 69.30M.
Overvalued
The company’s latest PE is -1.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.86M shares, decreasing 25.36% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 67.33K shares of this stock.
Financial Health
Currency: USD Updated: 2025-11-05The company's current financial score is 6.75, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 20.20M, representing a year-over-year increase of 25.52%, while its net profit experienced a year-over-year increase of 21.25%.
Score
Financials
6.56
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.54
Operational Efficiency
5.43
Growth Potential
7.09
Shareholder Returns
7.12
TELA Bio Inc's Company Valuation
Currency: USD Updated: 2025-11-05The company’s current valuation score is 8.30, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -1.14, which is -41.97% below the recent high of -0.66 and -330.49% above the recent low of -4.91.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 102/210
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-05The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for TELA Bio Inc is 6.00, with a high of 7.00 and a low of 2.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
5
analysts
Buy
Current Rating
5.400
Target Price
+318.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
110
Total
7
Median
9
Average
Company name
Ratings
Analysts
TELA Bio Inc
TELA
5
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-05The company’s current price momentum score is 5.25, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 1.46 and the support level at 1.03, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.278
Sell
MA10
1.360
Sell
MA20
1.425
Sell
MA50
1.522
Sell
MA100
1.681
Sell
MA200
1.729
Sell
Institutional Confidence
Currency: USD Updated: 2025-11-05The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 72.85%, representing a quarter-over-quarter decrease of 13.73%. The largest institutional shareholder is The Vanguard, holding a total of 1.91M shares, representing 4.83% of shares outstanding, with 1.35% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Nantahala Capital Management, LLC
EW Healthcare Partners
North Run Capital, LP
SilverArc Capital Management, LLC
Lytton (Laurence W)
Stonepine Capital Management, LLC
Dafna Capital Management, LLC
Perkins Capital Management, Inc.
Pentwater Capital Management LP
1
2
Risk Assessment
Currency: USD Updated: 2025-11-05The company’s current risk assessment score is 2.46, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.86
VaR
+5.58%
240-Day Maximum Drawdown
+71.66%
240-Day Volatility
+106.10%
Return
Best Daily Return
60 days
+11.38%
120 days
+19.75%
5 years
+24.62%
Worst Daily Return
60 days
-13.98%
120 days
-13.98%
5 years
-37.18%
Sharpe Ratio
60 days
-2.43
120 days
+0.89
5 years
-0.52
Risk Assessment
Maximum Drawdown
240 days
+71.66%
3 years
+92.60%
5 years
+94.84%
Return-to-Drawdown Ratio
240 days
-0.82
3 years
-0.32
5 years
-0.19
Skewness
240 days
-1.04
3 years
-0.90
5 years
-0.55
Volatility
Realised Volatility
240 days
+106.10%
5 years
+77.06%
Standardised True Range
240 days
+13.38%
5 years
+35.64%
Downside Risk-Adjusted Return
120 days
+163.86%
240 days
+163.86%
Maximum Daily Upside Volatility
60 days
+50.16%
Maximum Daily Downside Volatility
60 days
+46.19%
Liquidity
Average Turnover Rate
60 days
+0.24%
120 days
+0.45%
5 years
--
Turnover Deviation
20 days
-61.84%
60 days
-63.32%
120 days
-30.49%
Peer Comparison
Healthcare Equipment & Supplies
TELA Bio Inc
TELA
6.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
